BenevolentAI Investor Conference Presentation Deck slide image

BenevolentAI Investor Conference Presentation Deck

KEY SHAREHOLDER INFORMATION Listed on EuroNext; April 2022 REAKOU (Euronext Amsterdam: BAI) Offices in London, NYC and laboratories in Cambridge UK c.260 employees as at 31 December 2023 Top Shareholders (Dec'23): Ken Mulvany (co-founder) - 27.3% Temasek Life Sciences - 14.8% Link - 7.3% Zaoui - 7.3% (Odyssey sponsors) Ally Bridge Group - 5.9% Lansdowne Partners - 4.6% Evenstad Family - 4.4% Schroders - 3.8% Michael Brennan - 3.7% ACME Tools - 3.0% Strategic/partnership shareholders: Lilly 2.2% AstraZeneca 1.8% BOARD Dr. François Nader Acting CEO & Chair ELT Prof Sir Nigel Shadbolt Non-Executive Director Dr. François Nader Acting CEO & Chair Dr. Daniel Neil CTO Jean Raby Non-Executive & Senior Independent Director Dr. John Orloff Non-Executive Director Dr. Ivan Griffin Co-Founder Christina Busmalis CRO Dr. Olivier Brandicourt Non-Executive Director Marcello Damiani Non-Executive Director Catherine Isted CFO Anna Fullerton-Batten CPO Dr. Susan Liautaud Non-Executive Director Dr. Anne Phelan CSO Will Scrimshaw General Counsel Benevolent 14
View entire presentation